Central Beneficial Effects of Trimetazidine on Psychomotor Performance in Normal Healthy Volunteers
- PMID: 28626744
- PMCID: PMC5468786
- DOI: 10.4103/2277-9175.190994
Central Beneficial Effects of Trimetazidine on Psychomotor Performance in Normal Healthy Volunteers
Abstract
Background: Trimetazidine is a fatty oxidation inhibitor, leading to shifting of energy substrate from fatty acid oxidation toward glucose oxidation that leads to the reduction of oxygen requirement. The aims of the present study were to elucidate the effects of trimetazidine on psychomotor performance and vigilance on normal healthy volunteers.
Materials and methods: A total of 234 subjects (age 22-25 years) were recruited in this study. The volunteers were randomizing into two groups with 117 volunteers in each group. Group I received an inert starch capsule served as a control, and Group II received trimetazidine tablet 15 mg/day. The duration of therapy was 5 days. Test procedure was done at 9.00 a.m. on the psychomotor tester. Before the drug administration, prescore values were recorded and then after 5 days of therapy, the postscore values were recorded.
Results: The placebo did not demonstrate a significant effect on all psychomotor performances and flicker-fusion elements (P > 0.05). Trimetazidine therapy produced a highly significant effect on all components of psychomotor performances and flicker-fusion parameters (P < 0.001) compared with pretreatment era.
Conclusion: We conclude that trimetazidine improves psychomotor performance and vigilance in normal healthy volunteers through advancing total reaction time and critical flicker-fusion frequency.
Keywords: Critical flicker-fusion frequency; psychomotor performance; trimetazidine.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
A double-blind placebo-controlled investigation of the psychomotor profile of clopidogrel in healthy volunteers.J Cardiovasc Pharmacol. 2008 Dec;52(6):507-9. doi: 10.1097/FJC.0b013e31818fd7a3. J Cardiovasc Pharmacol. 2008. PMID: 19034035 Clinical Trial.
-
Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.Circ Res. 2003 Aug 8;93(3):e33-7. doi: 10.1161/01.RES.0000086964.07404.A5. Epub 2003 Jul 17. Circ Res. 2003. PMID: 12869392
-
Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease: evaluation of the protective role of the metabolic modulator trimetazidine.J Am Coll Cardiol. 2002 Feb 6;39(3):413-9. doi: 10.1016/s0735-1097(01)01768-5. J Am Coll Cardiol. 2002. PMID: 11823078 Clinical Trial.
-
Clinical benefits of trimetazidine in patients with recurrent angina.Coron Artery Dis. 2004 May;15 Suppl 1:S17-21. Coron Artery Dis. 2004. PMID: 15179124 Review.
-
Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.Rev Port Cardiol. 2000 Nov;19 Suppl 5:V35-9. Rev Port Cardiol. 2000. PMID: 11206102 Review.
Cited by
-
Trimetazidine Blocks Lipid Oxidation-Should it be Repurposed for Prevention and Treatment of Diabetic Ketoacidosis?J Diabetes Sci Technol. 2022 Sep;16(5):1063-1068. doi: 10.1177/19322968221100196. Epub 2022 Jun 2. J Diabetes Sci Technol. 2022. PMID: 35652624 Free PMC article. No abstract available.
-
Neuroprotective Effects of Trimetazidine against Cisplatin-Induced Peripheral Neuropathy: Involvement of AMPK-Mediated PI3K/mTOR, Nrf2, and NF-κB Signaling Axes.Oxid Med Cell Longev. 2024 Aug 20;2024:6612009. doi: 10.1155/2024/6612009. eCollection 2024. Oxid Med Cell Longev. 2024. PMID: 39502494 Free PMC article.
-
Trimetazidine Modulates Mitochondrial Redox Status and Disrupted Glutamate Homeostasis in a Rat Model of Epilepsy.Front Pharmacol. 2021 Oct 8;12:735165. doi: 10.3389/fphar.2021.735165. eCollection 2021. Front Pharmacol. 2021. PMID: 34690772 Free PMC article.
-
Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review.Brain Circ. 2020 Jun 26;6(2):70-80. doi: 10.4103/bc.bc_42_19. eCollection 2020 Apr-Jun. Brain Circ. 2020. PMID: 33033776 Free PMC article.
-
Trimetazidine May Potentially Confer Neuroprotective Effects against COVID-19-Induced Neurological Sequelae via Inhibition of Death-Associated Protein Kinase 1 (DAPK1) Signaling Pathways: An Evidenced-Based Hypothesis.Tanaffos. 2023 Feb;22(2):182-186. Tanaffos. 2023. PMID: 38628884 Free PMC article. No abstract available.
References
-
- Peng S, Zhao M, Wan J, Fang Q, Fang D, Li K. The efficacy of trimetazidine on stable angina pectoris: A meta-analysis of randomized clinical trials. Int J Cardiol. 2014;177:780–5. - PubMed
-
- Iqbal S, Baziany A, Hussain M, James S, Wright S, Hemmings S, et al. Trimetazidine as a potential neuroprotectant in transient global ischemia in gerbils: A behavioral and histological study. Brain Res. 2002;928:1–7. - PubMed
-
- Hassanzadeh G, Hosseini A, Pasbakhsh P, Akbari M, Ghaffarpour M, Takzare N, et al. Trimetazidine prevents oxidative changes induced in a rat model of sporadic type of Alzheimer's disease. Acta Med Iran. 2015;53:17–24. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources